Click on the links below to preview selected pages from this course.
- Predictive Testing is the Basis of Personalized Treatment
- Predictive versus Prognostic
- Response Rates to Common Therapies
- A prognostic factor is information concerning the patient that is used to help the clinician select the appropriate individuals for treatment with a s...
- Researchers have determined that only patients with tumors that demonstrate greater than 70% estrogen receptor (ER) positive cells will respond to hor...
- Types of Breast Cancer
- Incidence and Risk Factors
- Breast Cancer Classification
- Tumor Staging
- Use of Immunohistochemistry (IHC) for Breast Tumor Classification
- Adenocarcinoma is a very rare type of human breast cancer.
- Obesity, alcohol, and tobacco use are believed to have an impact on the risk for developing breast cancer.
- Regulation and Compliance with Predictive Markers
- Validation, Quality Control, Regulations -- Why?
- Validation Purpose
- Compliance Documentation
- Mandatory Proficiency Testing
- Laboratories accredited by the College of American Pathologists (CAP) that perform HER2 testing are not required to participate in proficiency testing...
- Test method verification or validation is required for all new test systems used in the laboratory prior to their use in patient testing.
- Theoretical Basis of Immunohistochemical Testing
- Basics of Immunohistochemistry (IHC)
- Variables Affecting IHC
- Types of Antibodies
- Staining Patterns
- Which factors may impact staining by IHC techniques? (Select all that apply.)
- IHC alone is used to determine a primary diagnosis.
- Hormone Receptor Testing
- Human Epidermal Growth Factor Receptor 2 (HER2)
- Introduction to Human Epidermal Growth Factor Receptor 2 (HER2)
- Immunohistochemistry (IHC) Testing Options For HER2
- Complimentary Testing Helps Assess HER2 Status
- Targeted Treatment Based on HER2 Status
- Impact of Variation in Test Results
- 2018 IHC Scoring Criteria from the American Society of Clinical Oncologists (ASCO) and the College of American Pathologists (CAP)
- HER2 over-expression in breast cancer is localized to chromosome 17.
- Only patients who over-express HER2 (eg, positive scores by IHC, CISH, or FISH) are candidates to receive Herceptin® (trastuzumab) treatment.
- HER2 Testing by In Situ Hybridization
- Specimen Handling and Fixation for Molecular and In Situ Methods
- Introduction to HER2 Methods Using In Situ Hybridization (ISH)
- Introduction to Fluorescent In Situ Hybridization (FISH) Methods
- Details of Fluorescent In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH) Method for HER2
- HER2 Test Method: Advantages and Disadvantages
- CISH and FISH Scoring Criteria from the 2018 American Society of Clinical Oncologists (ASCO) and College of American Pathologists (CAP) Guideline Reco...
- Using chromogenic in situ hybridization (CISH), a single copy of HER2 amplification appears under the light microscope as which of the following?
- What is the most commonly used, rapid, and cost effective method to assess HER2 status in clinical histology?
Level of instruction: Intermediate
Intended audience: This course is intended for histology bench technicians and technologists, supervisors, and administrators.
Author information: Joelle Weaver MAOM, HTL(ASCP), QIHC is a certified histotechnologist with a broad range of practical histology experience within the clinical histopathology setting. She has received qualification in immunohistochemistry (IHC) from the American Society for Clinical Pathology and Green Belt certification from Purdue University, West Lafayette, Indiana. Joelle's bachelor's degree was received from Bowling Green State University in Bowling Green, Ohio and her Master's Degree was awarded from Bluffton University in Bluffton, Ohio. She is a graduate of a NAACLS accredited histotechnology program and has held positions as adjunct professor, education coordinator, and program director at Columbus State Community College in Columbus Ohio (2002-2011). Joelle currently works as a histotechnologist and technical consultant in Louisville, Kentucky, specializing in IHC.
Reviewer information: Carla J. Shoffeitt, MSM, HT(ASCP) is the Manager of the Pathology Department of Emory St. Joseph’s Hospital of Emory Healthcare in Atlanta, Georgia. She holds a Master of Science Degree in Healthcare Management as well as a Bachelor of Science degree in Biology from Troy University, Troy, Alabama. She is certified as a Histotechnician and has 25 years of experience in the field of Histology.
Course description: Toxicity, side effects, and unpredictable effectiveness have been the hallmark of anti-cancer therapies used in the past to treat breast and other primary cancers. Targeted therapies have been developed which reduce patient risk and provide remarkable improvement in patient outcomes. This course will discuss how predictive markers/testing are used to select patients who are most likely to respond positively to a specific breast cancer treatment, including current testing methodologies and compliance standards.